[1] SHIVA R M, MICHAEL W, HSIN-FANG C, et al. Epidemiological studies of the association between reproductive lifespan characteristics and risk of type 2 diabetes and hypertension: a systematic review [J]. Maturitas, 2022, 18: 14-23.
[2] NESSAR A. Advanced glycation endproducts: role in pathology of diabetic complications[J]. Diabetes Res Clin Pract, 2005, 67: 3-21.
[3] Chinese Diabetes Society. Guidelines for prevention and treatment of type to diabetes in China (2020)[J]. Chin J Diabetes(中华糖尿病杂志), 2021, 13(4):315-409.
[4] ELRICK H, STIMMLER L, HLAD C J, et al. Plasma insulin response to oral andintravenous glucose administration[J]. J Clin Endocrinol Metab, 1964, 24: 1076-1082.
[5] AURELIE M, ELDEM S, DANTE S, et al. GLP-1 receptor agonists and coronary arteries: from mechanisms to events[J]. Front Pharmacol, 2022, 13: 856111. DOI: 10.3389/fphar.2022.856111.
[6] COSKUN T, SLOOP W, LOGHIN C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept[J]. Mol Metab, 2018, 18: 3-14.
[7] ANDERSEN A, LUND A, KNOP F K, et al. Glucagon-like peptide 1 in health and disease[J]. Nat Rev Endocrinol, 2018, 14(7): 390-403.
[8] FRANCIS S W, JONATHAN D D, MARIA B N G, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist[J]. JCI Insight, 2020, 5(17): 140532. DOI:10.1172/jci.insight.140532.
[9] OHWAKI K, FURIHATA K, MIMURA M, et al. 1024-P: effect of tirzepatide, a dual GIP and GLP-1 receptor agonist, on glycemic control and body weight in Japanese patients with T2DM[J]. Diabetes, 2019, 68: 1024-P. DOI:10.2337/db19-1024-P.
[10] FRIAS J P, NAUCK M A, VAN J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled, and active comparator-controlled phase 2 trial[J]. Lancet, 2018, 392(10160): 2180-2193.
[11] FRIAS J P, NAUCK M A, VAN J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens[J]. Diabetes Obes Metab, 2020, 22(6): 938-946.
[12] ROSENSTOCK J, WYSHAM C, FRIAS J P, et al. Efficacy and safety of a noveldual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial[J]. Lancet, 2021, 398(10295): 143-155.
[13] FRIAS J P, DAVIES M J, ROSENSTOCK J, et al. SURPASS-2 investigators. tirzepatide versus semaglutide once weekly in patients with type 2 diabetes[J]. N Engl J Med, 2021, 385(6): 503-515.
[14] LUDVIK B, GIORGINO F, JODAR E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial[J]. Lancet, 2021, 398(10300): 583-598.
[15] DEL P S, KAHN S E, PAVO I, et al. SURPASS-4 Investigators. Tirzepatideversus insulin glargine in type 2 diabetes and increased cardiovascularrisk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial[J]. Lancet, 2021, 398(10313): 1811-1824.
[16] DAHL D, ONISHI Y, NORWOOD P, et al. 80-LB: tirzepatide, a dual GIP/GLP-1 receptor agonist, is effective and safe when added to basal insulinfor treatment of type 2 diabetes (SURPASS-5) [J]. Diabetes, 2021, 70(Suppl.1):80. DOI: 10.2337/db21-80-LB.
[17] ANNE G, JOE F. Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities[N]. Fierce Pharma, 2022-10-06.
[18] REBITCH C B. Tirzepatide (mounjaro) for the treatment of type 2 diabetes mellitus [J]. American Family Physician, 2023, 108(1): 93.
[19] XIN-HUI P, BRYAN T. Efficacy and safety of tirzepatide in improving cardiometabolic of outcomes in patients with overweight or obesity. A systematic review and meta-analysis of randomized controlled trials[J]. J Am Coll Cardiol, 2023, 81(Suppl 8): 1774-1774.
[20] FURIHATA K, MIMURA H, HRVA S, et al. A phase 1 multiple-ascending dosestudy of tirzepatide in Japanese participants with type 2 diabetes[J]. Diabetes Obes Metab, 2022, 24(2): 239-246.
[21] FRIAS JP, NAUCK MA, VAN J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-likepeptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens[J]. Diabetes Obes Metab, 2020, 22(6): 938-946.
[22] FDA. Potential signals of serious risks/new safety information identified by the fda adverse event reporting system (FAERS)[S]. 2022.
[23] URVA S, QUINLAN T, LANDRY J, et al. Renal impairment has no impact on the clinical pharmacokinetics of tirzepatide[J]. Am Diabetes Assoc, 2020, 69(Suppl.1):971. DOI: 10.1055/s-0041-1727327.
[24] URVA S, QUINLAN T, LANDRY J, et al. Effects of hepatic impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide[J]. Clin Pharmacokinet, 2022, 61:1057-1067. DOI: 10.1007/s40262-022-01140-3.